GlassScriptPhysician profile
Kajal Shah
NPI 1356598106
$4,128.72
in general payments reported to CMS, 2019-2025
34 companies · $848 in 2025
The $848 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $451 · 2020: $48.89 · 2021: $155 · 2022: $378 · 2023: $1,375 · 2024: $872 · 2025: $848.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,794 · Education: $302.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,793.62 |
| Education | $301.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,701.10 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Abbott Laboratories | $268.19 | 2023 | Ensite |
| Pfizer INC. | $261.76 | 2023-2025 | |
| Scilex Pharmaceuticals INC. | $238.08 | 2021-2024 | Ztlido |
| Ucb, INC. | $229.41 | 2019-2025 | Briviact, Nayzilam |
| Lilly USA, LLC | $229.14 | 2019-2025 | Amyvid, Kisunla, Reyvow |
| Novartis Pharmaceuticals Corporation | $169.39 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $114.53 | 2019-2024 | Ajovy |
| Sumitomo Pharma America, INC. | $114.34 | 2023 | Aptiom |
| Lundbeck LLC | $94.76 | 2023-2025 | Vyepti |
| Supernus Pharmaceuticals, INC. | $71.01 | 2019-2021 | |
| Catalyst Pharmaceuticals, INC. | $70.44 | 2024 | |
| Eisai INC. | $49.79 | 2022-2023 | |
| Bioventus LLC | $47.55 | 2023-2024 | Gelsyn-3 |
| Novo Nordisk INC | $42.49 | 2019-2025 | Rybelsus, Ozempic |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $37.84 | 2019 | |
| Merck Sharp & Dohme LLC | $35.43 | 2024 | Capvaxive |
| Biohorizons Implant Systems INC. | $34.01 | 2019 | |
| Allergan, INC. | $32.99 | 2019 | |
| Grifols USA, LLC | $32.76 | 2025 | Prolastin-C Liquid |
| Glaxosmithkline, LLC. | $24.13 | 2023 | Shingrix, Bexsero |
| Depuy Synthes Sales INC. | $23.72 | 2024 | Orthovisc |
| Biohaven Pharmaceuticals, INC. | $22.76 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $22.49 | 2025 | Tezspire |
| Otsuka America Pharmaceutical, INC. | $19.60 | 2023 | Nuedexta |
| Cranial Technologies, INC | $18.83 | 2019 | |
| Amgen INC. | $18.33 | 2022 | |
| Sk Life Science, INC. | $17.88 | 2024 | |
| Sanofi Pasteur INC. | $17.34 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.37 | 2022 | |
| Sobi, INC | $13.87 | 2022 | |
| Currax Pharmaceuticals LLC | $13.32 | 2023 | Contrave |
| Azurity Pharmaceuticals, INC. | $13.16 | 2022 | |
| Arbor Pharmaceuticals, INC. | $11.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kajal Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.